ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia

Sunil K. Joshi, Jamie M. Keck, Christopher A. Eide, Daniel Bottomly, Elie Traer, Jeffrey W. Tyner, Shannon K. McWeeney, Cristina E. Tognon, Brian J. Druker

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalLeukemia
DOIs
StateAccepted/In press - Jan 1 2020

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Joshi, S. K., Keck, J. M., Eide, C. A., Bottomly, D., Traer, E., Tyner, J. W., McWeeney, S. K., Tognon, C. E., & Druker, B. J. (Accepted/In press). ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. Leukemia. https://doi.org/10.1038/s41375-020-0844-7